{"disease":{"id":"metastasis-skin","name":"metastasis skin"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03589339","title":"NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":145,"lead_sponsor_name":"Nanobiotix","has_results":false},{"nct_id":"NCT06362369","title":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"7 Hills Pharma, LLC","has_results":false},{"nct_id":"NCT06753136","title":"Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype","phase":"NA","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Istituto Oncologico Veneto IRCCS","has_results":false},{"nct_id":"NCT03972046","title":"Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"TriHealth Inc.","has_results":false}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}